AU2001276808A1 - A crystalline form of celecoxib - Google Patents

A crystalline form of celecoxib

Info

Publication number
AU2001276808A1
AU2001276808A1 AU2001276808A AU7680801A AU2001276808A1 AU 2001276808 A1 AU2001276808 A1 AU 2001276808A1 AU 2001276808 A AU2001276808 A AU 2001276808A AU 7680801 A AU7680801 A AU 7680801A AU 2001276808 A1 AU2001276808 A1 AU 2001276808A1
Authority
AU
Australia
Prior art keywords
crystalline form
celecoxib
ylübenzenesulfo
namide
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276808A
Inventor
Mehmet Bahar
Mehmet Goktepe
A. Halit Gunduz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fako Ilaclari AS
Original Assignee
Fako Ilaclari AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fako Ilaclari AS filed Critical Fako Ilaclari AS
Publication of AU2001276808A1 publication Critical patent/AU2001276808A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A new crystalline form of 4-Ä5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-ylÜbenzenesulfo namide of Formula I <CHEM> designated as Form I and a method for its production.o
AU2001276808A 2000-06-26 2001-06-26 A crystalline form of celecoxib Abandoned AU2001276808A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2000/01872A TR200001872A2 (en) 2000-06-26 2000-06-26 The new crystal form "Form I" of 4- [5- (4-Methylphenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide and the method for producing this product.
TR2000/01872 2000-06-26
PCT/TR2001/000025 WO2002000627A1 (en) 2000-06-26 2001-06-26 A crystalline form of celecoxib

Publications (1)

Publication Number Publication Date
AU2001276808A1 true AU2001276808A1 (en) 2002-01-08

Family

ID=21622570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276808A Abandoned AU2001276808A1 (en) 2000-06-26 2001-06-26 A crystalline form of celecoxib

Country Status (13)

Country Link
US (1) US6391906B2 (en)
EP (1) EP1167355B1 (en)
AT (1) ATE251142T1 (en)
AU (1) AU2001276808A1 (en)
CA (1) CA2350956C (en)
DE (1) DE60100873T2 (en)
EA (1) EA004470B1 (en)
ES (1) ES2206360T3 (en)
HK (1) HK1045155B (en)
IL (1) IL153615A0 (en)
PT (1) PT1167355E (en)
TR (1) TR200001872A2 (en)
WO (1) WO2002000627A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
DE10135027A1 (en) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Use of trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl derivatives in the treatment and / or prophylaxis of Obestias and its concomitant and / or secondary diseases
NZ532346A (en) 2001-09-18 2005-10-28 Onconova Therapeutics Inc Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
US6579988B2 (en) * 2001-09-18 2003-06-17 Onconova Therapeutics, Inc. Processes for the preparation of 1,5-diarylpyrazoles
WO2004061433A1 (en) * 2002-12-30 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (en) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ Multi-component solid phase containing at least one active pharmaceutical ingredient
AU2002251329A1 (en) * 2002-04-25 2003-11-10 Generics (Uk) Limited Novel crystalline forms of celecoxib and other compounds
WO2003091221A1 (en) * 2002-04-25 2003-11-06 Generics [Uk] Limited Celecoxib forms
KR20050013553A (en) * 2002-05-24 2005-02-04 파마시아 코포레이션 Synthesis of diaryl pyrazoles
MXPA05000232A (en) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2565409T3 (en) * 2004-04-01 2016-04-04 Zoetis Services Llc Crystalline Pyrazole Derivative
WO2006024930A1 (en) * 2004-09-01 2006-03-09 Pharmacia & Upjohn Company Llc Novel co-crystals between polyethylene glycols and 5-phenylpyrazolyl-1-benzenesulfonamides
ES2416330T3 (en) * 2004-10-28 2013-07-31 Dsm Ip Assets B.V. Stable needle-shaped crystals of natamycin.
WO2006079923A2 (en) * 2005-01-31 2006-08-03 Pharmacia & Upjohn Company Llc Form iv crystalline celecoxib
CA2686830C (en) * 2007-05-25 2015-09-08 Exxonmobil Upstream Research Company A process for producing hydrocarbon fluids combining in situ heating, a power plant and a gas plant
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
US20110213159A1 (en) * 2010-03-01 2011-09-01 Vamsee Krishna Muppidi Process for preparation of celecoxib crystalline form
CN103524416B (en) * 2013-10-29 2016-08-17 湖北华世通生物医药科技有限公司 A kind of Novel celecoxib crystal form A and preparation method thereof
CN103539739B (en) * 2013-10-30 2016-02-10 中美华世通生物医药科技（武汉）有限公司 A kind of Novel celecoxib crystal form B and preparation method thereof
CN103508958A (en) * 2013-10-30 2014-01-15 中美华世通生物医药科技（武汉）有限公司 Novel celecoxib crystal form C and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
KR100229343B1 (en) * 1993-11-30 1999-11-01 윌리암스 로저 에이 Substituted pyrazolyl benzene sulfoneamides for the treatment of inflammation
KR100444802B1 (en) * 1995-05-25 2004-12-17 지.디. 썰 엘엘씨 Method of preparing 3-haloalkyl-1h-pyrazoles
AU760888B2 (en) * 1999-01-14 2003-05-22 Merck Frosst Canada & Co. Synthesis of 4-((5-substituted or unsubstituted phenyl) -3-substituted -1H-pyrazol -1-yl) benzenesulfonamides
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)

Also Published As

Publication number Publication date
TR200001872A3 (en) 2002-01-21
HK1045155B (en) 2004-05-28
WO2002000627A1 (en) 2002-01-03
EP1167355B1 (en) 2003-10-01
US20020016351A1 (en) 2002-02-07
CA2350956A1 (en) 2001-12-26
CA2350956C (en) 2005-08-23
ES2206360T3 (en) 2004-05-16
EA004470B1 (en) 2004-04-29
PT1167355E (en) 2004-02-27
US6391906B2 (en) 2002-05-21
DE60100873T2 (en) 2004-07-22
ATE251142T1 (en) 2003-10-15
EP1167355A1 (en) 2002-01-02
HK1045155A1 (en) 2002-11-15
EA200300067A1 (en) 2003-06-26
IL153615A0 (en) 2003-07-06
DE60100873D1 (en) 2003-11-06
TR200001872A2 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
AU2001276808A1 (en) A crystalline form of celecoxib
AU2003229953A1 (en) Phthalazinone derivatives
AU2002211216A1 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
WO2003028728A8 (en) 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
EP1466898A4 (en) Beta-amyloid protein production/secretion inhibitors
IL159931A0 (en) Process for producing pyridine compound
AU2003223340A1 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
WO2003011849A8 (en) Process for the production of beraprost and its salts
MXPA04004806A (en) N-heteroarylnicotinamide derivatives.
AU2002358911A1 (en) Method of monitoring/controlling thysanoptera
AU2002365378A1 (en) Process for preparing 3,3&#39;,6,6&#39;-tetraalkyl-2,2&#39;-biphenols and 3,3&#39;,6,6&#39;-tetraalkyl-5,5&#39;-dihalo-2,2&#39;-biphenols
WO2004039776A3 (en) A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
EP1434762A4 (en) 4&#39;-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
AU2002359985A1 (en) Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
EG24798A (en) Pyrazole compound.
MXPA03012073A (en) Heterocyclic amide derivatives.
MXPA02012483A (en) Method for producing 4-bromine-aniline derivatives.
AU2002359044A1 (en) Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
EP1306368A3 (en) 3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor
HUP0103088A2 (en) Production of beraprost ester by selective reduction
CA2258960A1 (en) A process for preparing naphthyridones and intermediates
WO2003008386A3 (en) Process for the preparation of the enantiomeric forms of 2-substituted 2-(2,5-dioxoimidazolidin-1-yl)-acetic acid derivatives
AU2002331209A1 (en) Method for production of coated paper with extreme whiteness
AU2002344651A1 (en) Process for production of pyrazole compounds